Estimation of efficacy of glabridin to reduce visceral fat area
- Conditions
- one
- Registration Number
- JPRN-UMIN000027340
- Lead Sponsor
- KSO Corporation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 34
Not provided
1.Subjects under medication. 2.Subjects taking medicine and food that might impact the outcome measures. 3.Patients with serious disease such as renal disease, heart disease, respiratory illness, internal secretion disease, diabetes 4.Subjects who has allergy to experimental diet. 5.Subjects who are under treatment for or have a history of drug addiction and/or alcoholism. 6.Subjects who has metal in the body wherethe CT scanning measurement position 7.Susbjects who has implantable meicalequipments such as pacemaker and defibrillator. 8.Subjects who has Claustrophobia. 9.Shift workers, late-night workers 10.Subjects who have been diagnosed with familial. 11.Subjects who are planning to become pregnant during the study or are pregnant or lactating. 12.Subjects who are participating or planning to participate in other clinical studies to examine effects of food, medicine or cosmetics. 13.Subjects who are judged as unsuitable for the study by the investigator for other reasons.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method visceral fat area
- Secondary Outcome Measures
Name Time Method body weight, body fat percentage, abdominal subcutanious fat area, abdominal total fat area, Waist circumference, hip circumference, circumference hip waist circumference ratio, CHO, LDL, HDL, triglyceride, fasting blood glucose, HbA1c, insuliin, adiponectin, AST,ALT,HOMA-R